The STOP HER2 (NCT05721248) and HEROES (French trial not registered on ClinicalTrials.gov) trials are exploring the potential of circulating tumor DNA (ctDNA) to revolutionize the management of HER2-positive cancers. Here, ERBB2 is linked to neoplasm.